Update for Phase 1 Trial of University of Queensland COVID-19 Vaccine

The University of Queensland COVID-19 vaccine candidate has generated considerable interest for its innovative approach and potential.

Both the safety and immunogenicity data analysed from the phase 1 trial so far are very positive.

The data also showed that a fragment of protein (gp41)—present in HIV—used to stablise the vaccine is causing an antibody response. The response is causing diagnostic interference in some HIV tests.

There is no possibility the vaccine causes infection, and routine follow-up tests have confirmed there is no HIV virus present. The Phase 1 trial will continue, where further analysis of the data will show how long the antibodies persist, with studies so far showing that levels are already falling.

However, CSL has agreed with UQ and the Australian Government that it will not progress the vaccine candidate to Phase 2/3 clinical trials.

Participants were advised of this development and support is being made available to them. For any further enquiries regarding this study, please call (07) 3707 2720

Unprecedented numbers of Queenslanders have volunteered to be part of this trial, and much has been learned about the underlying platform technology. Their efforts have improved our understanding of COVID-19, and their contribution and willingness to participate has helped Nucleus Network to achieve our goal of advancing medicine, improving lives.